Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of Eplontersen in Healthy Volunteers and hATTR Amyloidosis
NCT03728634Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Dec 2018
- Primary completion
- Feb 2020
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of eplontersen in hereditary transthyretin amyloidosis (hATTR), sponsored by Ionis Pharmaceuticals. Started Dec 2018; status: completed.
02
Drugs
eplontersen
03
Conditions
hereditary transthyretin amyloidosis (hATTR)
Beyond the preview
Go deeper on NCT03728634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03728634.